Diagnosis and treatment of prostate cancer-related bone disease
Clinical Investigation · 2011
DOI: 10.4155/cli.10.25 ↗At a glance
Journal article in Clinical Investigation, 2011. Written by Tilman Todenhoefer and 5 co-authors. Cited 2 times so far (Crossref); 177 references.
Abstract (original language)
Bone disease is a major problem for patients suffering from advanced prostate cancer. It can result either from metastatic osseous lesions severely impairing patients’ quality of life and overall survival or from androgen deprivation therapy (ADT) and secondary osteopenia osteoporosis associated with an increased risk for skeletal-related events. Activation of osteoclasts is essential for both ADT-induced osteoporosis and metastatic bone disease. The individual risk of developing fractures during ADT can be evaluated by analysis of bone mineral density and fracture risk models. General measures can be recommended to all patients receiving ADT. Bisphosphonates, RANKL inhibitors and selective estrogen receptor modulators are effective tools to reduce bone loss during ADT. Besides imaging, serum and urine markers are gaining increasing importance in diagnosis and follow up of bone metastases. Bisphosphonates are the current standard of bone-targeted treatment for patients with bone metastases. The RANKL inhi...
Cite
APA
Todenhoefer, T., Gakis, G., Schilling, D., Feil, G., Schwentner, C., & Stenzl, A. (2011). Diagnosis and treatment of prostate cancer-related bone disease. Clinical Investigation. https://doi.org/10.4155/cli.10.25
Vancouver
Todenhoefer T, Gakis G, Schilling D, Feil G, Schwentner C, Stenzl A. Diagnosis and treatment of prostate cancer-related bone disease. Clinical Investigation. 2011. doi:10.4155/cli.10.25
BibTeX
@article{Todenhoefer2011,
author = {Todenhoefer, Tilman and Gakis, Georgios and Schilling, David and Feil, Gerhard and Schwentner, Christian and Stenzl, Arnulf},
title = {Diagnosis and treatment of prostate cancer-related bone disease},
journal = {Clinical Investigation},
year = {2011},
doi = {10.4155/cli.10.25}
}
EUVIMED